Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Level 5 - mechanism / opinion, no new human data
Theoretical model and narrative synthesis with no new empirical human data reported
PubMed 20083042 · doi:10.1016/S1474-4422(09)70299-6
What was done
The authors synthesized existing literature on Alzheimer's disease pathophysiology to propose a hypothetical model describing the temporal dynamics of biomarkers across preclinical and clinical stages.
What was found
The abstract reports no empirical numbers or quantitative measurements. It describes a hypothetical cascade model wherein biomarkers of brain beta-amyloidosis (decreased CSF Abeta42, increased amyloid PET retention) become abnormal first in cognitively normal individuals. After a variable lag phase, biomarkers of neuronal injury and neurodegeneration (increased CSF tau, MRI cerebral atrophy, and decreased FDG-PET uptake) become abnormal and correlate with clinical symptom severity.
Why it matters
This framework formalized the temporal sequence of Alzheimer's disease pathology, providing a foundational paradigm for biomarker-based disease staging and clinical trial design.
Limits
As a conceptual model, the paper presents no primary patient dataset, sample size, or quantitative testing in the abstract. The hypothesized order and individual variability in biomarker trajectories require empirical validation in prospective longitudinal cohorts.
Cited by
- supports Neurodegenerative conditions like Alzheimer's begin 20 to 30 years prior to the presentation of clinical symptoms.